In Response to the ADM FDA Safety Communication on March 31, 2021

Please access the PDF below to read the response to the FDA safety communication on March 31, 2021, titled Acellular Dermal Matrix (ADM) Products Used in Implant-Based Breast Reconstruction Differ in Complication Rates.

Bulletin 18-8​

Bulletin 19-1​

Bulletin 19-2

Bulletin 19-3

Bulletin 19-4

Bulletin 19-5​

Bulletin 19-6

Bulletin 19-7

Bulletin 20-1